STOCK TITAN

ZLAB insider files to sell 6,641 ADSs after restricted vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Zai Lab Limited (ZLAB) Form 144 filing reports a proposed sale of 6,641 American Depositary Shares acquired by restricted stock vesting on 08/15/2025. The filing lists the broker as Fidelity Brokerage Services LLC and an aggregate market value of $240,645.27. The filing shows 421,725,450 shares outstanding and an approximate sale date of 08/18/2025 on NASDAQ. The filer certifies no undisclosed material adverse information and discloses no other sales in the past three months.

Positive

  • Transparent disclosure of acquisition method (restricted stock vesting) and planned sale details
  • No sales reported by the filer in the past three months
  • Filer attestation that no undisclosed material adverse information is known

Negative

  • Insider sale of vested ADSs (6,641 shares) may be perceived negatively by some investors despite small size

Insights

TL;DR: Insider sale of vested restricted ADSes is disclosed; size is small relative to outstanding shares.

The filing documents a routine proposed sale of 6,641 ADSs received from restricted stock vesting on 08/15/2025, scheduled to be sold through Fidelity on or about 08/18/2025. With an aggregate market value of $240,645.27 versus 421,725,450 shares outstanding, the transaction is immaterial to the companys capitalization. The filing also affirms the filer is unaware of any undisclosed material adverse information. No prior sales in the past three months are reported, reducing likelihood of a larger selling pattern in this short window.

TL;DR: Disclosure follows Rule 144 requirements; documentation indicates compensation-origin shares being liquidated.

The notice specifies acquisition by restricted stock vesting and payment characterized as compensation, consistent with employee or insider compensation events. The use of a major broker and the filers attestation about material information align with standard compliance practice. The small absolute size relative to outstanding shares suggests limited governance or control implications from this single filing.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does ZLAB Form 144 report?

The filing reports a proposed sale of 6,641 American Depositary Shares acquired via restricted stock vesting on 08/15/2025, to be sold through Fidelity Brokerage Services LLC around 08/18/2025.

How much are the shares worth in this Form 144?

The aggregate market value reported is $240,645.27 for the 6,641 ADSs.

Is this sale large compared to ZLABs outstanding shares?

No; the filing lists 421,725,450 shares outstanding, making this filing immaterial in percentage terms.

Was the acquisition part of compensation for the filer?

Yes. The securities were acquired by restricted stock vesting and the nature of payment is listed as compensation.

Did the filer report other sales in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.
Zai Lab Limited

NASDAQ:ZLAB

ZLAB Rankings

ZLAB Latest News

ZLAB Latest SEC Filings

ZLAB Stock Data

2.09B
106.96M
1.74%
42.53%
4.26%
Biotechnology
Pharmaceutical Preparations
Link
China
SHANGHAI